Insider Trading activities of Ariad Pharmaceuticals Inc insiders. , Part 4

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ariad Pharmaceuticals Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ariad Pharmaceuticals Inc since year 2005. (See page 1 of this report.) Table 2 shows the detailed insider transactions of Ariad Pharmaceuticals Inc since 2005. The reporting company's ticker symbol is ARIA. The reporting company's CIK number is 884731.
The total value of stock buying since 2005 is $9,530,946.
The total value of stock sales since 2005 is $52,752,828.
The total value of stock option exercises since 2005 is $11,507,365.


Go to page:  1   2   3   4 

Table 2. Detailed insider stock purchases, sales, and option exercises of Ariad Pharmaceuticals Inc insiders (ARIA) , Part 4
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2012-03-27 Cantor Maria E (SVP, Corporate Affairs) Sale 18,000 16.23 292,140
2012-03-26 Cantor Maria E (SVP, Corporate Affairs) Sale 6,000 16.00 96,000
2012-03-26 Cantor Maria E (SVP, Corporate Affairs) Option Ex 6,000 3.08 18,480
2012-03-26 Haluska Frank (SVP, Clinical R&D, CMO) Sale 3,000 16.00 48,000
2012-03-26 Haluska Frank (SVP, Clinical R&D, CMO) Option Ex 3,000 2.39 7,170
2012-03-26 Dodion Pierre F (SVP, Corp. Dev. & Operations) Sale 25,000 16.50 412,500
2012-03-26 Dodion Pierre F (SVP, Corp. Dev. & Operations) Option Ex 25,000 5.49 137,250
2012-03-26 Clackson Timothy P (President, R&D, CSO) Sale 33,561 16.17 545,888
2012-03-26 Clackson Timothy P (President, R&D, CSO) Option Ex 7,500 6.39 47,925
2012-03-26 Berstein David L (Senior VP, Chief IP Officer) Sale 19,375 16.00 310,000
2012-03-26 Berstein David L (Senior VP, Chief IP Officer) Option Ex 11,375 4.19 47,661
2012-03-23 Haluska Frank (SVP, Clinical R&D, CMO) Sale 6,667 15.41 102,718
2012-03-23 Keane Raymond T (SVP General Counsel & CCO) Sale 10,533 15.41 162,271
2012-03-23 Dodion Pierre F (SVP, Corp. Dev. & Operations) Sale 24,901 15.08 375,457
2012-03-23 Fitzgerald Edward M (Executive VP, CFO) Sale 12,933 15.41 199,245
2012-03-23 Clackson Timothy P (President, R&D, CSO) Sale 15,333 15.40 236,204
2012-03-23 Berstein David L (Senior VP, Chief IP Officer) Sale 10,533 15.41 162,271
2012-03-22 Cantor Maria E (SVP, Corporate Affairs) Option Ex 18,000 .00 0
2012-03-22 Haluska Frank (SVP, Clinical R&D, CMO) Option Ex 13,333 .00 0
2012-03-22 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 32,333 .00 0
2012-03-22 Keane Raymond T (SVP General Counsel & CCO) Option Ex 26,333 .00 0
2012-03-22 Dodion Pierre F (SVP, Corp. Dev. & Operations) Option Ex 20,333 .00 0
2012-03-22 Fitzgerald Edward M (Executive VP, CFO) Option Ex 32,333 .00 0
2012-03-22 Clackson Timothy P (President, R&D, CSO) Option Ex 38,333 .00 0
2012-03-22 Berstein David L (Senior VP, Chief IP Officer) Option Ex 26,333 .00 0
2012-03-22 Berger Harvey J M D (Chairman & CEO) Option Ex 97,666 .00 0
2012-03-20 Cantor Maria E (SVP, Corporate Affairs) Sale 14,000 15.02 210,224
2012-03-20 Haluska Frank (SVP, Clinical R&D, CMO) Sale 15,000 15.02 225,240
2012-03-20 Keane Raymond T (SVP General Counsel & CCO) Sale 8,400 15.02 126,151
2012-03-20 Dodion Pierre F (SVP, Corp. Dev. & Operations) Sale 12,980 15.01 194,803
2012-03-20 Fitzgerald Edward M (Executive VP, CFO) Sale 31,200 15.02 468,592
2012-03-20 Clackson Timothy P (President, R&D, CSO) Sale 36,400 15.02 546,618
2012-03-20 Berstein David L (Senior VP, Chief IP Officer) Sale 18,800 15.02 282,319
2012-03-20 Berger Harvey J M D (Chairman & CEO) Option Ex 25,000 .00 0
2012-03-19 Cantor Maria E (SVP, Corporate Affairs) Option Ex 35,000 .00 0
2012-03-19 Haluska Frank (SVP, Clinical R&D, CMO) Option Ex 30,000 .00 0
2012-03-19 Keane Raymond T (SVP General Counsel & CCO) Option Ex 21,000 .00 0
2012-03-19 Dodion Pierre F (SVP, Corp. Dev. & Operations) Option Ex 59,000 .00 0
2012-03-19 Fitzgerald Edward M (Executive VP, CFO) Option Ex 78,000 .00 0
2012-03-19 Clackson Timothy P (President, R&D, CSO) Option Ex 91,000 .00 0
2012-03-19 Berstein David L (Senior VP, Chief IP Officer) Option Ex 47,000 .00 0
2012-03-16 Clackson Timothy P (President, R&D, CSO) Option Ex 15,064 4.12 62,063
2012-03-10 Berger Harvey J M D (Chairman & CEO) Option Ex 160,000 .00 0
2012-02-28 Lamarche Jay R (Director) Option Ex 20,000 4.44 88,800
2012-02-28 Berstein David L (Senior VP, Chief IP Officer) Sale 11,375 15.50 176,312
2012-02-28 Berstein David L (Senior VP, Chief IP Officer) Option Ex 11,375 4.04 46,011
2012-02-23 Dodion Pierre F (SVP, Corp. Dev. & Operations) Sale 25,000 15.00 375,000
2012-02-23 Dodion Pierre F (SVP, Corp. Dev. & Operations) Option Ex 25,000 5.49 137,250
2012-02-23 Berstein David L (Senior VP, Chief IP Officer) Sale 4,100 15.00 61,500
2012-02-21 Haluska Frank (SVP, Clinical R&D, CMO) Sale 4,500 14.51 65,277
2012-02-21 Haluska Frank (SVP, Clinical R&D, CMO) Option Ex 4,500 2.39 10,755
2012-02-21 Berstein David L (Senior VP, Chief IP Officer) Sale 35,100 14.50 509,020
2012-02-21 Berstein David L (Senior VP, Chief IP Officer) Option Ex 22,800 3.90 88,920
2012-02-14 Keane Raymond T (SVP General Counsel & CCO) Sale 12,500 15.13 189,175
2012-02-14 Keane Raymond T (SVP General Counsel & CCO) Option Ex 12,500 1.30 16,250
2012-02-14 Clackson Timothy P (President, R&D, CSO) Sale 76,436 15.12 1,155,788
2012-02-14 Clackson Timothy P (President, R&D, CSO) Option Ex 76,436 4.05 309,336
2012-01-27 Lamarche Jay R (Director) Sale 26,900 15.05 404,979
2012-01-26 Lamarche Jay R (Director) Sale 3,100 15.04 46,627
2011-07-26 Berger Harvey J M D (Chairman & CEO) Option Ex 20,837 4.80 100,017
2011-06-07 Clackson Timothy P (President, R&D, CSO) Option Ex 60,000 5.65 339,000
2011-06-07 Berstein David L (Senior VP, Chief IP Officer) Option Ex 60,000 5.65 339,000
2011-05-09 Lamarche Jay R (Director) Option Ex 25,000 5.65 141,250
2011-04-11 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 50,000 .00 0
2011-04-11 Dodion Pierre F (Senior VP, Corp. Development) Option Ex 25,000 .00 0
2011-04-11 Fitzgerald Edward M (Executive VP, CFO) Option Ex 52,000 .00 0
2011-04-11 Clackson Timothy P (President, R&D, CSO) Option Ex 52,000 .00 0
2011-04-11 Berstein David L (Senior VP, Chief IP Officer) Option Ex 22,000 .00 0
2011-04-11 Berger Harvey J M D (Chairman & CEO) Option Ex 104,000 .00 0
2011-03-25 Lamarche Jay R (Director) Sale 25,000 7.01 175,275
2011-03-22 Haluska Frank (VP, Clinical R&D, CMO) Option Ex 13,334 .00 0
2011-03-22 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 32,334 .00 0
2011-03-22 Keane Raymond T (SVP General Counsel & CCO) Option Ex 26,334 .00 0
2011-03-22 Dodion Pierre F (Senior VP, Corp. Development) Option Ex 20,334 .00 0
2011-03-22 Fitzgerald Edward M (Executive VP, CFO) Option Ex 32,334 .00 0
2011-03-22 Clackson Timothy P (President, R&D, CSO) Option Ex 38,334 .00 0
2011-03-22 Berstein David L (Senior VP, Chief IP Officer) Option Ex 26,334 .00 0
2011-03-22 Berger Harvey J M D (Chairman & CEO) Option Ex 97,667 .00 0
2011-02-02 Lamarche Jay R (Director) Sale 25,000 6.48 161,925
2011-01-11 Lamarche Jay R (Director) Sale 25,000 5.37 134,325
2010-12-20 Lamarche Jay R Sale 25,000 5.00 125,125
2010-10-26 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Buy 3,000 3.70 11,100
2010-10-26 Clackson Timothy P (Pres., R & D., Chief Sci. Off.) Buy 10,000 3.70 37,000
2010-05-17 Keane Raymond T (SVP General Counsel & CCO) Sale 10,256 4.09 41,947
2010-05-12 Dodion Pierre F (Senior VP, Chief Medical Officer) Sale 19,292 4.29 82,762
2009-10-01 Iuliucci John D (Senior VP, Development) Sale 70,000 2.17 151,550
2009-10-01 Iuliucci John D (Senior VP, Development) Option Ex 70,000 .75 52,500
2009-08-04 Dodion Pierre F (Senior VP, Chief Medical Officer) Buy 5,714 1.75 9,999
2009-08-04 Berger Harvey J M D (Chairman & CEO) Buy 1,714,286 1.75 3,000,000
2008-01-18 Lamarche Jay R (Director) Option Ex 10,000 .00 0
2008-01-18 Kishbauch Michael D (Director) Option Ex 10,000 .00 0
2008-01-17 Lamarche Jay R (Director) Option Ex 10,000 .00 0
2008-01-17 Sobel Burton E (Director) Option Ex 10,000 .00 0
2007-07-11 Clackson Timothy P (SrVP, Chief Scientific Officer) Option Ex 6,400 5.06 32,403
2007-07-09 Berger Harvey J M D (Chairman and CEO) Option Ex 107,372 4.33 465,457
2007-06-28 Wyatt Elizabeth H S (Director) Option Ex 40,000 3.35 134,200
2007-06-20 Smith Sandford D (Director) Option Ex 45,000 2.76 124,199
2007-05-17 Berger Harvey J M D (Chairman & Chief Exec Officer) Option Ex 224,455 2.00 448,910
2007-01-17 Kishbauch Michael D (Director) Option Ex 10,000 .00 0
2006-03-10 Iuliucci John D (Senior VP, Chief Dev. Off.) Option Ex 2,633 4.19 11,032
2006-03-10 Clackson Timothy P (SVP, Chief Scientific Officer) Option Ex 1,300 3.94 5,122
2006-03-10 Berger Harvey J M D (Chairman and CEO) Option Ex 22,000 4.19 92,180
2006-02-15 Lamarche Jay R (Director) Sale 777 6.51 5,058
2006-02-15 Lamarche Jay R (Director) Option Ex 34,000 4.19 142,460
2006-02-14 Lamarche Jay R (Director) Sale 25,300 6.54 165,462
2006-01-18 Sobel Burton E (Director) Sale 4,147 6.50 26,955
2006-01-09 Sobel Burton E (Director) Sale 5,853 6.50 38,044
Go to page:  1   2   3   4 

Insider trading activities including stock purchases, stock sales, and option exercises of ARIA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ariad Pharmaceuticals Inc (symbol ARIA, CIK number 884731) see the Securities and Exchange Commission (SEC) website.